Abderrahman Ouban1. 1. Department of Pathology, Alfaisal University College of Medicine, Riyadh, Kingdom of Saudi Arabia. aouban@hotmail.com.
Abstract
BACKGROUND: Laryngeal squamous cell carcinomas (LSCCs) are tumours with a high incidence of treatment failure and recurrence. Recent strategies to improve the five-year survival rate and to decrease the rates of recurrence and metastases did not improve outcomes significantly. Research efforts in recent years have started focusing on discovering biomarkers of prognosis and management in LSCCs. Filamin-A reportedly has been associated with metastatic disease in a recent study. Analysis of this protein's expression in LSCCs is lacking in the literature. MATERIALS AND METHODS: This study analysed the expression of filamin-A, using immunohistochemistry, in a tissue microarray of 80 cases of laryngeal squamous cell cancers. Clinical-pathological parameters were analysed according to filamin-A expression in the tissue microarray. Furthermore, a review of possible mechanisms of this protein in cancer, in general, was presented, along with a review of the protein's expression in other head and neck tumours. RESULTS: A significant majority of laryngeal squamous cell cancers exhibited positive expression of filamin-A protein. All the filamin-A positive tumours expressed it in their cytoplasm. Significant correlation between filamin-A expression and grade, stage, lymph node status and metastases were found. CONCLUSION: The above may suggest an important role for filamin-A in LSCCs. Overall, filamin-A expression in laryngeal cancer is in line with evidence seen in other head and neck cancers. Further studies are in order to pinpoint the exact role of this protein in LSCCs, and its possible utilization in the management of these difficult-to-treat tumours.
BACKGROUND: Laryngeal squamous cell carcinomas (LSCCs) are tumours with a high incidence of treatment failure and recurrence. Recent strategies to improve the five-year survival rate and to decrease the rates of recurrence and metastases did not improve outcomes significantly. Research efforts in recent years have started focusing on discovering biomarkers of prognosis and management in LSCCs. Filamin-A reportedly has been associated with metastatic disease in a recent study. Analysis of this protein's expression in LSCCs is lacking in the literature. MATERIALS AND METHODS: This study analysed the expression of filamin-A, using immunohistochemistry, in a tissue microarray of 80 cases of laryngeal squamous cell cancers. Clinical-pathological parameters were analysed according to filamin-A expression in the tissue microarray. Furthermore, a review of possible mechanisms of this protein in cancer, in general, was presented, along with a review of the protein's expression in other head and neck tumours. RESULTS: A significant majority of laryngeal squamous cell cancers exhibited positive expression of filamin-A protein. All the filamin-A positive tumours expressed it in their cytoplasm. Significant correlation between filamin-A expression and grade, stage, lymph node status and metastases were found. CONCLUSION: The above may suggest an important role for filamin-A in LSCCs. Overall, filamin-A expression in laryngeal cancer is in line with evidence seen in other head and neck cancers. Further studies are in order to pinpoint the exact role of this protein in LSCCs, and its possible utilization in the management of these difficult-to-treat tumours.
Authors: Yuanyi Feng; Ming Hui Chen; Ivan P Moskowitz; Ashley M Mendonza; Luis Vidali; Fumihiko Nakamura; David J Kwiatkowski; Christopher A Walsh Journal: Proc Natl Acad Sci U S A Date: 2006-12-15 Impact factor: 11.205
Authors: Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester Journal: CA Cancer J Clin Date: 2017-01-17 Impact factor: 508.702
Authors: Mary E W Collier; Camille Ettelaie; Benjamin T Goult; Anthony Maraveyas; Alison H Goodall Journal: Thromb Haemost Date: 2017-11-30 Impact factor: 5.249
Authors: Roble G Bedolla; Yu Wang; Alfredo Asuncion; Karim Chamie; Salma Siddiqui; Maria M Mudryj; Thomas J Prihoda; Javed Siddiqui; Arul M Chinnaiyan; Rohit Mehra; Ralph W de Vere White; Paramita M Ghosh Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531
Authors: Joanna E Gawecka; Genevieve S Griffiths; Barbro Ek-Rylander; Joe W Ramos; Michelle L Matter Journal: PLoS One Date: 2010-06-23 Impact factor: 3.240
Authors: J W Fox; E D Lamperti; Y Z Ekşioğlu; S E Hong; Y Feng; D A Graham; I E Scheffer; W B Dobyns; B A Hirsch; R A Radtke; S F Berkovic; P R Huttenlocher; C A Walsh Journal: Neuron Date: 1998-12 Impact factor: 17.173
Authors: Scott Gehler; Massimiliano Baldassarre; Yatish Lad; Jennifer L Leight; Michele A Wozniak; Kristin M Riching; Kevin W Eliceiri; Valerie M Weaver; David A Calderwood; Patricia J Keely Journal: Mol Biol Cell Date: 2009-05-20 Impact factor: 4.138
Authors: Irène Baccelli; Albrecht Stenzinger; Vanessa Vogel; Berit Maria Pfitzner; Corinna Klein; Markus Wallwiener; Martina Scharpff; Massimo Saini; Tim Holland-Letz; Hans-Peter Sinn; Andreas Schneeweiss; Carsten Denkert; Wilko Weichert; Andreas Trumpp Journal: Oncotarget Date: 2014-09-30
Authors: Yundi Guo; Ming Li; Guanghui Bai; Xiaoning Li; Zhongwen Sun; Jie Yang; Lu Wang; Jing Sun Journal: Oncol Lett Date: 2018-09-20 Impact factor: 2.967